ardigen phenaid orange background

PhenAID Platform


Identify Better Drug Candidates
with Morphological Profiling

PhenAID platform streamlines the identification and profiling of small molecule drug candidates, leveraging the power of multimodal data. By combining molecular structures, High Content Screening images, and multi-omics data, it significantly elevates the drug discovery process. The platform enables the performance of a variety of predictive and generative tasks through easy-to-configure AI-based pipelines.

Watch a short video about PhenAID platform WATCH the DEMO

 

JUMP-CP SUPPORTING PARTNER

Check our tool to explore JUMP-CP data. JUMP-CP Data Explorer

Ardigen phenAID Platform Capabilities

PhenAID Bridges the Gap Between Cell Imaging and Small Molecule Design

Combine Varied Data Types Through Artificial Intelligence

Ardigen phenAID Platform
at Any Stage of Your Research:

Our solution will improve your drug design process through seamless AI-lab integration. The AI platform is a comprehensive solution that fits into your drug discovery process and can be used out-of-the-box in every step of the process. We can increase your chances of obtaining a drug candidate that will successfully pass the clinical trials. Whether you are just starting your project and looking for compounds to screen, or if you have already gathered phenotypic screening outcomes, we can help.

With our platform you are able to:

  • find the targets and off-targets of your molecules;
  • narrow the chemical search space;
  • optimize your compounds to obtain the desired phenotype;
  • assign Mode of Action to chemical compounds.

Accelerate Drug Discovery Process

Drug discovery process with PhenAID Platform

As the standard drug design process is expensive and time-consuming, it can be improved with our AI-based solutions. Our Platform allows you to:

  • exhaustively explore the chemical space of up to ~10^8 molecules;
  • design focused libraries which can improve the hit rate to 40%;
  • carry out the in silico optimization process yielding optimized compounds in even 2 AI-lab cycles;
  • prevent undesired phenotypic effect at an early stage;
  • efficiently obtain outcomes from Cell Painting assays.

Increasing Your Success Rate
with Solutions Tailored to Your Needs

What Level of Customization Do You Need?

 

Whether you are just starting or have been in the field for some time, we fit into your needs by providing two approaches to
collaboration. Our out-of-the-box Licensed Virtual Screening Platform gives you access to a cloud-based app as a ready-to-use
solution. Whereas, Our Customized Virtual Screening Service enables integration with your internal data, pipelines, and system to
maximize the utility of its usage.

Virtual Screening Platform

Licensed Virtual Screening Platform
or Customized Virtual Screening Service

  • Licensed Virtual Screening Platform

  • Our platform can be delivered as a cloud-based app with
    intuitive modules for data management, experiments analysis,
    and results reporting. By uploading data to your private and
    secure account in the cloud, you can easily perform analyzes of
    HCS images and molecular structures using our AI-based
    features.
  • Customized Virtual Screening Service

  • If you are looking to integrate our AI features into your internal
    pipelines, we will delegate a team of experts to deploy the
    platform on your internal infrastructure. During the integration
    process, we will adapt the modules to best fit into your drug
    design process and provide training and support to ensure high
    usability of the platform.

Ardigen phenAID platform

Ardigen is a Supporting Partner of the JUMP-CP Consortium


JUMP-CP consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set, corresponding to both genetic and chemical perturbations. It’s members include 10 leading pharmaceutical companies (Amgen, AstraZeneca, Bayer, Biogen, Eisai, Janssen Pharmaceutica NV, Merck KGaA, Pfizer, Servier, and Takeda) and two non-profit research organizations, including the Broad Institute of MIT and Harvard and Ksilink.


We are providing deep learning expertise to the consortium, leveraging a web application to facilitate the exploration of the JUMP-CP Cell Painting dataset.
Check our tool to explore JUMP-CP data. JUMP-CP Data Explorer

Take a closer look
at our platform

Main features:

  • Cloud-based system ready to be used in secure cloud environments such as AWS, Azure, or an internal IT infrastructure.
  • User-friendly application that can be easily operated by any biologist.
  • Perform powerful AI analysis of HCS data through easy-to-build pipelines.
  • Use custom set of modalities to identify hits, classify mode of actions, predict properties and screen your library.
  • Automatically checks data quality and segments single-cells.
  • Interactive data visualization and built-in report generator.

Case Studies

Click on the button below and discover our solutions in detail

 

Check the capabilities of phenAID platform in:


Multimodal mode of action prediction


Deep learning approach to analyze HCS images

Check out our case studies

Our science

We are driven by science and collaborations!

Since 2015, we’ve had the opportunity to execute a variety of exciting and complex projects, both for our clients and internally.
A high degree of trust and confidentiality is the foundation for our business. That’s why we are always very excited to share the results of our scientific projects.
We publish and present materials, such as journal publications, posters, case studies and technical notes whenever possible, through which we aim to show the scope of our scientific team’s experience.

On demand webinars

The AI Advantage: Game – Changing Insights in HCS with Cell Painting
26 October 2023 The AI Advantage: Game – Changing Insights in HCS with Cell Painting

    Decoding Immuno-Peptidomics: A New Era in Therapeutic Target Identification
    15 June 2023 Decoding Immuno-Peptidomics: A New Era in Therapeutic Target Identification

      Leveraging Single-Cell Transcriptomics for the Discovery of New Therapeutic
      6 December 2022 Leveraging Single-Cell Transcriptomics for the Discovery of New Therapeutic

        Ardigen's Technical Blog

        Meet us at upcoming events

        • Coming soon
          23-25 April 2024
          London, United Kingdom
          8th Annual Immuno-Oncology Summit Europe
        • 25 April 2024
          Cambridge, UK
          ELRIG: AI in Drug Discovery Forum
        • 29-30 April 2024
          Hinxton, UK
          Target to Patient
        • 22-23 May 2024
          Basel, Switzerland
          Discovery Europe 2024
        • 27-29 May 2024
          Barcelona, Spain
          SLAS Europe 2024
        • 03-06 June 2024
          Boston, US
          Bio International Convention
        • 10-11 August 2024
          Pennsylvania, US
          BiotechX USA 2024
        • 30 September - 03 October 2024
          Boston, US
          Discovery on Target
        • 15-17 October 2024
          Basel, Switzerland
          Festival of Biologics 2024
        • 05-07 November 2024
          Boston, US
          The 16th PEGS Europe Protein & Antibody Engineering Summit
        • 15-17 April 2024
          Boston, US
          Bio IT
        • 15-17 April 2024
          San Diego, US
          Festival of Biologics San Diego 2024
        • 21-22 March 2024
          Boston, US
          NextGen Omics US 2024
        • 21-22 March 2024
          Boston, US
          Synthetic Biology US
        • 19-21 March 2024
          Boston, US
          Precision Medicine in Inflammatory Bowel Disease Summit
        • 13-14 March 2024
          Basel, Switzerland
          RNA Leaders
        • 11-12 March 2024
          London, United Kingdom
          AI in Drug Discovery
        • 3-7 February 2024
          Boston, US
          SLAS USA
        • 24 - 26 January 2024
          Santa Clara, US
          PMWC
        • 24 - 25 May 2023
          Brussels, Belgium
          SLAS Europe
        • 25 February - 1 March 2023
          San Diego, USA
          SLAS
        • 25 - 27 January 2023
          Santa Clara, USA
          PMWC
        • 24 - 25 October 2022
          Wroclaw, Poland
          Central European Technology Forum
        • 4 - 5 October 2022
          UK, London
          ELRIG 2022
        • 18 - 20 September 2022
          Boston, USA
          SBI2
        • 26 -28 June
          PMWC 2022
        • 15-16 February 2022
          digital
          Boost your way to successful therapy. AI for Drug Discovery Days”
        • 23 - 26 June
          digital
          SLAS Europe 2021
        • 14 - 18 June
          digital
          PMWC 2021 COVID Virtual
        • 15 - 17 June
          digital
          Pharma R&D Week Virtual
        • 9-10 June
          digital
          Precision in Drug Discovery & Preclinical Virtual Summit
        • 17 - 19 May 2021
          Biomarkers Week
        • 14 April
          digital
          Spatial Biology Europe conference
        • 25 - 26 March
          digital
          AI in Healthcare & Pharma Virtual Summit

        Contact us

        Are you interested in Biomedical Imaging platform based solutions?

          • https://ardigen.com/wp-content/uploads/2024/02/Untitled-design-14.png Livia Legg Chief Commercial Officer
          • https://ardigen.com/wp-content/uploads/2023/12/Kaja-Milanowska-Zabel-PhD.png Kaja Milanwoska Zabel, PhD, MBA Business Development Executive
          • https://ardigen.com/wp-content/uploads/2021/05/Group-115@2x.jpg Agata Mieżaniec, PhD Senior Business Development Manager
          • https://ardigen.com/wp-content/uploads/2023/01/Sean-modified.png Sean Melville Senior Business Development Manager
          • https://ardigen.com/wp-content/uploads/2023/02/Agnieszka_Plociennikowska1.png Agnieszka Płóciennikowska, PhD Business Development Manager
          • https://ardigen.com/wp-content/uploads/2023/01/DSC01813-modified.png Aneta Kuczewska Business Development Manager
          Go up